Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jun 7;116(6):775-778.
doi: 10.1093/jnci/djae042.

Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer

Marc Arbyn  1   2 , Pegah Rousta  1 , Laia Bruni  3   4 , Lina Schollin Ask  5   6 , Partha Basu  7
Affiliations
Comment

Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer

Marc Arbyn et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence of cervical cancer stratified by human papillomavirus vaccination status and age at vaccination (see legend), observed in linkage studies conducted in Sweden (14), Denmark (15), and Scotland (1), joining individual patient data from vaccination and cancer registries. The X-axis in the two plots on top expresses the years at follow-up, whereas the plot at the bottom expresses the years since start of screening invitation. aFor Scotland, restricted to subjects who were completely vaccinated.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Palmer TJ, Kavanagh K, Cuschieri K, et al.Invasive cervical cancer incidence following bivalent HPV vaccination—a population-based observational study of age at immunisation, dose, and deprivation. J Natl Cancer Inst. 2024. doi:10.1093/jnci/djad263 - DOI - PubMed
    1. Pagliusi SR, Teresa AM.. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004;23(5):569-578. - PubMed
    1. IARC, NCI. Primary End-points for Prophylactic HPV Vaccine Trials IARC Working Group Report. Vol. 7, 2014. https://www.iarc.who.int/wp-content/uploads/2018/07/Prophylactic_HPV_Vac... - PubMed
    1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents: a review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100B:1-475. - PMC - PubMed
    1. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP.. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5(5):CD009069. - PMC - PubMed

MeSH terms

Substances